An Inflammation-Related Nine-Gene Signature to Improve Prognosis Prediction of Lung Adenocarcinoma

Figure 3

The prognostic value of the inflammation-related prognostic model for LUAD. (a) The survival assays between high-risk and low-risk groups. (b) ROC assays of the identified immune-related risk signature in 500 LUAD patients. (c) The risk score distribution of LUAD patients in 500 LUAD patients. (d) Survival status and survival time of each LUAD patient.

(a)

(b)

(c)

(d)